Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-?) mediated killing by contacting the cells or administering the agent that inhibits autophagy.

Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Abstract: A composite oxidation catalyst for use in an exhaust system for treating an exhaust gas produced by a vehicular compression ignition internal combustion engine is disclosed. The composite oxidation catalyst comprises a honeycomb flow-through substrate monolith and two catalyst washcoat zones arranged axially in series on and along the substrate surface.

Abstract: Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: A composite oxidation catalyst (18, 20) for use in an exhaust system for treating an exhaust gas produced by a vehicular compression ignition internal combustion engine (30) and upstream of a particulate matter filter (44, 50) in the exhaust system comprises a substrate (5) having a total length L and a longitudinal axis and having a substrate surface extending axially between a first substrate end (I) and a second substrate end (O); and three or more catalyst washcoat zones (1, 2, 3; or 1, 2, 3, 4) arranged axially in series on and along the substrate surface, wherein a first catalyst washcoat zone (1) having a length L1, wherein L1<L, is defined at one end by the first substrate end (I) and at a second end by a first end (19, 21) of a second catalyst washcoat zone (2) having a length L2, wherein L2<L, wherein the first catalyst washcoat zone (1) comprises a first refractory metal oxide support material and two or more platinum group metal components supported thereon comprising both platinum and palla

Abstract: An exhaust gas treatment system includes in order: an intake for receiving an exhaust gas from a lean burn combustion engine; an injector for the provision of a nitrogenous reductant; a close-coupled vanadium-containing SCR catalyst composition; one or more downstream PGM-containing oxidation catalyst compositions, wherein the close-coupled vanadium-containing SCR catalyst composition includes cerium in a Ce:V molar ratio of greater than 0.3.

Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: A compression ignition internal combustion engine (30) for a heavy-duty diesel vehicle comprising an exhaust system (32) comprising a composite oxidation catalyst (12, 42) and a soot filter substrate (44, 50) disposed downstream from the composite oxidation catalyst comprising: a substrate (5), preferably a honeycomb flow-through substrate monolith, having a total length L and a longitudinal axis and having a substrate surface extending axially between a first substrate end (I) and a second substrate end (O); two catalyst washcoat zones (1, 2) arranged axially in series on and along the substrate surface, wherein a first catalyst washcoat zone (1) having a length L1 and comprising a first catalyst washcoat layer (9), wherein L1<L, is defined at one end by the first substrate end (I) and at a second end by a first end (15) of a second catalyst washcoat zone (2) having a length L2 and comprising a second catalyst washcoat layer (11), wherein L2<L, wherein the second catalyst washcoat zone (2) is defined a

Abstract: A composite, zone-coated, dual-use ammonia (AMOX) and nitric oxide oxidation catalyst (12) comprises: a substrate (5) having a total length L and a longitudinal axis and having a substrate surface extending axially between a first substrate end (I) and a second substrate end (O); two or more catalyst washcoat zones (1; 2) comprised of a first catalyst washcoat layer (9) comprising a refractory metal oxide support material and one or more platinum group metal components supported thereon and a second catalyst washcoat layer (11) different from the first catalyst washcoat layer (9) and comprising a refractory metal oxide support material and one or more platinum group metal components supported thereon, which two or more catalyst washcoat zones (1; 2) being arranged axially in series on and along the substrate surface, wherein a first catalyst washcoat zone (1) having a length L1, wherein L1<L, is defined at one end by the first substrate end (I) and at a second end (13) by a first end (15) of a second catal

Abstract: An emissions control device for treating or removing pollutants from an exhaust gas produced by an internal combustion engine is disclosed. The emissions control device comprises a solid foam layer disposed on a substrate, wherein the solid foam layer disposed on a substrate has an open cell structure and comprises a particulate material which is a catalytic material comprising a catalytically active metal supported on a support material.

Abstract: A method of coating a substrate with a foam is described. The method comprises: (a) introducing a foam into a substrate comprising a plurality of channels through open ends of the channels at a first end of the substrate; and (b) applying at least one of (i) a vacuum to open ends of the channels at a second end of the substrate and (ii) a pressure to the open ends of the channels at the first end of the substrate; wherein the foam comprises a particulate material, and wherein the foam is particle stabilized.

Abstract: The present invention provides fully human antibodies that bind to the RET receptor tyrosine kinase, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for treating diseases, disorders, or conditions associated with expression, activation, or signaling of the RET receptor tyrosine kinase gene, or a rearranged form thereof, including cancerous conditions and the pain associated with the cancer, or for alleviating the pain associated with other conditions attributed to, at least in part, by expression, activation or signaling of RET. The antibodies specific for RET may be useful for slowing tumor cell growth or tumor cell proliferation and also for alleviating the pain associated with the cancer and other conditions. The antibodies may also be useful for diagnosis of a disease, disorder or condition associated with RET activation or signaling.

Abstract: A system, method, and computer program product for self-identification of a device. The disclosure utilizes generation of a public/private key pair, within the device itself, and completes at least a portion of an authentication process within the device itself using a securely stored private key that never leaves the device. By not transferring the private key away from the device, potential vulnerabilities of known systems due to transfer of identification information during or after manufacturing is effectively eliminated.

Abstract: Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.

Abstract: A composite oxidation catalyst (18, 20) for use in an exhaust system for treating an exhaust gas produced by a vehicular compression ignition internal combustion engine (30) and upstream of a particulate matter filter (44, 50) in the exhaust system comprises a substrate (5) having a total length L and a longitudinal axis and having a substrate surface extending axially between a first substrate end (I) and a second substrate end (O); and three or more catalyst washcoat zones (1, 2, 3; or 1, 2, 3, 4) arranged axially in series on and along the substrate surface, wherein a first catalyst washcoat zone (1) having a length L1, wherein L1<L, is defined at one end by the first substrate end (I) and at a second end by a first end (19, 21) of a second catalyst washcoat zone (2) having a length L2, wherein L2<L, wherein the first catalyst washcoat zone (1) comprises a first refractory metal oxide support material and two or more platinum group metal components supported thereon comprising both platinum and palla

Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.

Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-?) mediated killing by contacting the cells or administering the agent that inhibits autophagy.